Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Michael Bristow to Middle Aged

This is a "connection" page, showing publications Michael Bristow has written about Middle Aged.

 
Connection Strength
  
 
 
1.253
  
  1. Shamoun F, De Marco T, DeMets D, Mei C, Lindenfeld J, Saxon LA, Boehmer JP, Leigh J, Yong P, Feldman AM, Bristow MR. Impact of Degree of Left Ventricular Remodeling on Clinical Outcomes From Cardiac Resynchronization Therapy. JACC Heart Fail. 2019 04; 7(4):281-290.
    View in: PubMed
    Score: 0.040
  2. Parikh KS, Fiuzat M, Davis G, Neely M, Blain-Nelson P, Whellan DJ, Abraham WT, Adams KF, Felker GM, Liggett SB, O'Connor CM, Bristow MR. Dose Response of ?-Blockers in Adrenergic Receptor Polymorphism Genotypes. Circ Genom Precis Med. 2018 08; 11(8):e002210.
    View in: PubMed
    Score: 0.038
  3. Piccini JP, Connolly SJ, Abraham WT, Healey JS, Steinberg BA, Al-Khalidi HR, Dignacco P, van Veldhuisen DJ, Sauer WH, White M, Wilton SB, Anand IS, Dufton C, Marshall DA, Aleong RG, Davis GW, Clark RL, Emery LL, Bristow MR. A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. Am Heart J. 2018 05; 199:51-58.
    View in: PubMed
    Score: 0.037
  4. Leary PJ, Kronmal RA, Bluemke DA, Buttrick PM, Jones KL, Kao DP, Kawut SM, Krieger EV, Lima JA, Minobe W, Ralph DD, Tedford RJ, Weiss NS, Bristow MR. Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Multi-Ethnic Study of Atherosclerosis and Beta-Blocker Effect on Remodeling and Gene Expression Trial). Am J Cardiol. 2018 01 15; 121(2):256-261.
    View in: PubMed
    Score: 0.036
  5. Sucharov CC, Kao DP, Port JD, Karimpour-Fard A, Quaife RA, Minobe W, Nunley K, Lowes BD, Gilbert EM, Bristow MR. Myocardial microRNAs associated with reverse remodeling in human heart failure. JCI Insight. 2017 01 26; 2(2):e89169.
    View in: PubMed
    Score: 0.034
  6. Bristow MR, Saxon LA, Feldman AM, Mei C, Anderson SA, DeMets DL. Lessons Learned and Insights Gained in?the?Design, Analysis, and Outcomes of?the COMPANION Trial. JACC Heart Fail. 2016 07; 4(7):521-535.
    View in: PubMed
    Score: 0.033
  7. Lindenfeld J, Cleveland JC, Kao DP, White M, Wichman S, Bristow JC, Peterson V, Rodegheri-Brito J, Korst A, Blain-Nelson P, Sederberg J, Hunt SA, Gilbert EM, Ambardekar AV, Minobe W, Port JD, Bristow MR. Sex-related differences in age-associated downregulation of human ventricular myocardial ?1-adrenergic receptors. J Heart Lung Transplant. 2016 Mar; 35(3):352-361.
    View in: PubMed
    Score: 0.032
  8. Kao DP, Lowes BD, Gilbert EM, Minobe W, Epperson LE, Meyer LK, Ferguson DA, Volkman AK, Zolty R, Borg CD, Quaife RA, Bristow MR. Therapeutic Molecular Phenotype of ?-Blocker-Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy. Circ Cardiovasc Genet. 2015 Apr; 8(2):270-83.
    View in: PubMed
    Score: 0.030
  9. Aleong RG, Sauer WH, Davis G, Bristow MR. New-onset atrial fibrillation predicts heart failure progression. Am J Med. 2014 Oct; 127(10):963-71.
    View in: PubMed
    Score: 0.029
  10. Aleong RG, Sauer WH, Davis G, Murphy GA, Port JD, Anand IS, Fiuzat M, O'Connor CM, Abraham WT, Liggett SB, Bristow MR. Prevention of atrial fibrillation by bucindolol is dependent on the beta1389 Arg/Gly adrenergic receptor polymorphism. JACC Heart Fail. 2013 Aug; 1(4):338-344.
    View in: PubMed
    Score: 0.027
  11. Aleong RG, Sauer WH, Robertson AD, Liggett SB, Bristow MR. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol. 2013 Feb; 6(1):137-43.
    View in: PubMed
    Score: 0.026
  12. Kao DP, Davis G, Aleong R, O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Murphy GA, Sauer W, Bristow MR. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013 Mar; 15(3):324-33.
    View in: PubMed
    Score: 0.026
  13. O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Walsh R, Nelson P, Medway A, Davis G, Robertson AD, Port JD, Carr J, Murphy GA, Lazzeroni LC, Abraham WT, Liggett SB, Bristow MR. Combinatorial pharmacogenetic interactions of bucindolol and ?1, a2C adrenergic receptor polymorphisms. PLoS One. 2012; 7(10):e44324.
    View in: PubMed
    Score: 0.026
  14. O'Connor CM, Fiuzat M, Swedberg K, Caron M, Koch B, Carson PE, Gattis-Stough W, Davis GW, Bristow MR. Influence of global region on outcomes in heart failure ?-blocker trials. J Am Coll Cardiol. 2011 Aug 23; 58(9):915-22.
    View in: PubMed
    Score: 0.024
  15. Bader FM, Gilbert EM, Mehta NA, Bristow MR. Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure. Congest Heart Fail. 2010 Nov-Dec; 16(6):265-70.
    View in: PubMed
    Score: 0.022
  16. Calalb MB, McKinsey TA, Newkirk S, Huynh K, Sucharov CC, Bristow MR. Increased phosphorylation-dependent nuclear export of class II histone deacetylases in failing human heart. Clin Transl Sci. 2009 Oct; 2(5):325-32.
    View in: PubMed
    Score: 0.021
  17. Saxon LA, Olshansky B, Volosin K, Steinberg JS, Lee BK, Tomassoni G, Guarnieri T, Rao A, Yong P, Galle E, Leigh J, Ecklund F, Bristow MR. Influence of left ventricular lead location on outcomes in the COMPANION study. J Cardiovasc Electrophysiol. 2009 Jul; 20(7):764-8.
    View in: PubMed
    Score: 0.020
  18. Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali JK, Jaski B, Lindenfeld J, O'Connor C, Steinberg JS, Leigh J, Yong P, Kosorok MR, Feldman AM, DeMets D, Bristow MR. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation. 2009 Feb 24; 119(7):969-77.
    View in: PubMed
    Score: 0.020
  19. Sharkey SW, Maron BJ, Nelson P, Parpart M, Maron MS, Bristow MR. Adrenergic receptor polymorphisms in patients with stress (tako-tsubo) cardiomyopathy. J Cardiol. 2009 Feb; 53(1):53-7.
    View in: PubMed
    Score: 0.019
  20. De Marco T, Wolfel E, Feldman AM, Lowes B, Higginbotham MB, Ghali JK, Wagoner L, Kirlin PC, Kennett JD, Goel S, Saxon LA, Boehmer JP, Mann D, Galle E, Ecklund F, Yong P, Bristow MR. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study. J Card Fail. 2008 Feb; 14(1):9-18.
    View in: PubMed
    Score: 0.018
  21. Lindenfeld J, Feldman AM, Saxon L, Boehmer J, Carson P, Ghali JK, Anand I, Singh S, Steinberg JS, Jaski B, DeMarco T, Mann D, Yong P, Galle E, Ecklund F, Bristow M. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation. 2007 Jan 16; 115(2):204-12.
    View in: PubMed
    Score: 0.017
  22. Lowes BD, Zolty R, Minobe WA, Robertson AD, Leach S, Hunter L, Bristow MR. Serial gene expression profiling in the intact human heart. J Heart Lung Transplant. 2006 May; 25(5):579-88.
    View in: PubMed
    Score: 0.016
  23. Pittenger B, Gill EA, Holcslaw TL, Bristow MR. Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy. Am J Cardiol. 2004 Dec 01; 94(11):1459-62.
    View in: PubMed
    Score: 0.015
  24. Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, Lowes BD, Hattler B, Abraham WT, Olson L, Krueger S, Thaneemit-Chen S, Hare JM, Loeb HS, Domanski MJ, Eichhorn EJ, Zelis R, Lavori P. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation. 2004 Sep 14; 110(11):1437-42.
    View in: PubMed
    Score: 0.015
  25. Mallabone M, Labib D, Abdelhaleem A, Dykstra S, Thompson RB, Paterson DI, Thompson SK, Hasanzadeh F, Mikami Y, Rivest S, Flewitt J, Feng Y, Macdonald M, King M, Bristow M, Kolman L, Howarth AG, Lydell CP, Miller RJH, Fine NM, White JA. Sex-based differences in the phenotypic expression and prognosis of idiopathic non-ischaemic cardiomyopathy: a cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2024 May 31; 25(6):804-813.
    View in: PubMed
    Score: 0.014
  26. Hess CN, Hsia J, Carroll IA, Nehler MR, Ruf W, Morrow DA, Nicolau JC, Berwanger O, Szarek M, Capell WH, Johri S, Pursley MS, Gupta R, Meehan PS, Franchi F, Effron MB, Marshall D, Graybill CA, Huebler SP, Keuer T, Bristow MR, Bonaca MP. Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial. Arterioscler Thromb Vasc Biol. 2023 08; 43(8):1572-1582.
    View in: PubMed
    Score: 0.013
  27. Abraham WT, Gilbert EM, Lowes BD, Minobe WA, Larrabee P, Roden RL, Dutcher D, Sederberg J, Lindenfeld JA, Wolfel EE, Shakar SF, Ferguson D, Volkman K, Linseman JV, Quaife RA, Robertson AD, Bristow MR. Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med. 2002 Nov; 8(11):750-60.
    View in: PubMed
    Score: 0.013
  28. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002 May 02; 346(18):1357-65.
    View in: PubMed
    Score: 0.012
  29. Thornton CS, Huntley K, Berenger BM, Bristow M, Evans DH, Fonseca K, Franko A, Gillrie MR, Lin YC, Povitz M, Shafey M, Conly JM, Tremblay A. Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values. Antimicrob Resist Infect Control. 2022 02 05; 11(1):28.
    View in: PubMed
    Score: 0.012
  30. Purmah Y, Cornhill A, Lei LY, Dykstra S, Mikami Y, Satriano A, Labib D, Flewitt J, Rivest S, Sandonato R, Seib M, Howarth AG, Lydell CP, Heydari B, Merchant N, Bristow M, Kolman L, Fine NM, White JA. Mid-wall striae fibrosis predicts heart failure admission, composite heart failure events, and life-threatening arrhythmias in dilated cardiomyopathy. Sci Rep. 2022 02 02; 12(1):1739.
    View in: PubMed
    Score: 0.012
  31. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001 Dec; 81(2-3):141-9.
    View in: PubMed
    Score: 0.012
  32. Purmah Y, Lei LY, Dykstra S, Mikami Y, Cornhill A, Satriano A, Flewitt J, Rivest S, Sandonato R, Seib M, Lydell CP, Howarth AG, Heydari B, Merchant N, Bristow M, Fine N, Gaztanaga J, White JA. Right Ventricular Ejection Fraction for the Prediction of Major Adverse Cardiovascular and Heart Failure-Related Events: A Cardiac MRI Based Study of 7131 Patients With Known or Suspected Cardiovascular Disease. Circ Cardiovasc Imaging. 2021 03; 14(3):e011337.
    View in: PubMed
    Score: 0.011
  33. Beldhuis IE, Myhre PL, Bristow M, Claggett B, Damman K, Fang JC, Fleg JL, McKinlay S, Lewis EF, O'Meara E, Pitt B, Shah SJ, Vardeny O, Voors AA, Pfeffer MA, Solomon SD, Desai AS. Spironolactone in Patients With Heart?Failure, Preserved Ejection Fraction, and Worsening Renal Function. J Am Coll Cardiol. 2021 03 09; 77(9):1211-1221.
    View in: PubMed
    Score: 0.011
  34. Kinugawa K, Minobe WA, Wood WM, Ridgway EC, Baxter JD, Ribeiro RC, Tawadrous MF, Lowes BA, Long CS, Bristow MR. Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression. Circulation. 2001 Feb 27; 103(8):1089-94.
    View in: PubMed
    Score: 0.011
  35. Lowes BD, Higginbotham M, Petrovich L, DeWood MA, Greenberg MA, Rahko PS, Dec GW, LeJemtel TH, Roden RL, Schleman MM, Robertson AD, Gorczynski RJ, Bristow MR. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol. 2000 Aug; 36(2):501-8.
    View in: PubMed
    Score: 0.011
  36. Haywood ME, Cocciolo A, Porter KF, Dobrinskikh E, Slavov D, Graw SL, Reece TB, Ambardekar AV, Bristow MR, Mestroni L, Taylor MRG. Transcriptome signature of ventricular arrhythmia in dilated cardiomyopathy reveals increased fibrosis and activated TP53. J Mol Cell Cardiol. 2020 02; 139:124-134.
    View in: PubMed
    Score: 0.011
  37. Piccini JP, Abraham WT, Dufton C, Carroll IA, Healey JS, van Veldhuisen DJ, Sauer WH, Anand IS, White M, Wilton SB, Aleong R, Rienstra M, Krueger SK, Ayala-Paredes F, Khaykin Y, Merkely B, Miloradovic V, Wranicz JK, Ilkhanoff L, Ziegler PD, Davis G, Emery LL, Marshall D, Kao DP, Bristow MR, Connolly SJ. Bucindolol for the Maintenance of Sinus?Rhythm in a Genotype-Defined HF?Population: The GENETIC-AF Trial. JACC Heart Fail. 2019 07; 7(7):586-598.
    View in: PubMed
    Score: 0.010
  38. Gerdes AM, Onodera T, Tamura T, Said S, Bohlmeyer TJ, Abraham WT, Bristow MR. New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material. J Card Fail. 1998 Dec; 4(4):343-8.
    View in: PubMed
    Score: 0.010
  39. Sweet ME, Cocciolo A, Slavov D, Jones KL, Sweet JR, Graw SL, Reece TB, Ambardekar AV, Bristow MR, Mestroni L, Taylor MRG. Transcriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure. BMC Genomics. 2018 Nov 12; 19(1):812.
    View in: PubMed
    Score: 0.010
  40. Zisman LS, Asano K, Dutcher DL, Ferdensi A, Robertson AD, Jenkin M, Bush EW, Bohlmeyer T, Perryman MB, Bristow MR. Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart. Circulation. 1998 Oct 27; 98(17):1735-41.
    View in: PubMed
    Score: 0.010
  41. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, Ferguson DA, Bristow MR. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol. 1998 May; 31(6):1336-40.
    View in: PubMed
    Score: 0.009
  42. Quaife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, Bristow MR. Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol. 1998 Jan 15; 81(2):247-50.
    View in: PubMed
    Score: 0.009
  43. Bristow MR, Abraham WT, Yoshikawa T, White M, Hattler BG, Crisman TS, Lowes BD, Robertson AD, Larrabee P, Gilbert EM. Second- and third-generation beta-blocking drugs in chronic heart failure. Cardiovasc Drugs Ther. 1997 May; 11 Suppl 1:291-6.
    View in: PubMed
    Score: 0.009
  44. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996 Dec 01; 94(11):2807-16.
    View in: PubMed
    Score: 0.009
  45. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996 Dec 01; 94(11):2817-25.
    View in: PubMed
    Score: 0.009
  46. Quaife RA, Gilbert EM, Christian PE, Datz FL, Mealey PC, Volkman K, Olsen SL, Bristow MR. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol. 1996 Oct 01; 78(7):779-84.
    View in: PubMed
    Score: 0.008
  47. Leary PJ, Tedford RJ, Bluemke DA, Bristow MR, Heckbert SR, Kawut SM, Krieger EV, Lima JA, Masri CS, Ralph DD, Shea S, Weiss NS, Kronmal RA. Histamine H2 Receptor Antagonists, Left?Ventricular Morphology, and Heart?Failure?Risk: The MESA Study. J Am Coll Cardiol. 2016 Apr 05; 67(13):1544-1552.
    View in: PubMed
    Score: 0.008
  48. Focaccio A, Peeters G, Movsesian M, Roden R, Eki Y, Krall J, Bristow MR. Mechanism of action of OPC-8490 in human ventricular myocardium. Circulation. 1996 Feb 15; 93(4):817-25.
    View in: PubMed
    Score: 0.008
  49. White M, Yanowitz F, Gilbert EM, Larrabee P, O'Connell JB, Anderson JL, Renlund D, Mealey P, Abraham WT, Bristow MR. Role of beta-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol. 1995 Dec 15; 76(17):1271-6.
    View in: PubMed
    Score: 0.008
  50. Gilbert EM, Hershberger RE, Wiechmann RJ, Movsesian MA, Bristow MR. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest. 1995 Dec; 108(6):1524-32.
    View in: PubMed
    Score: 0.008
  51. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995 May; 25(6):1225-31.
    View in: PubMed
    Score: 0.008
  52. Feldman AM, She L, McNamara DM, Mann DL, Bristow MR, Maisel AS, Wagner DR, Andersson B, Chiariello L, Hayward CS, Hendry P, Parker JD, Racine N, Selzman CH, Senni M, Stepinska J, Zembala M, Rouleau J, Velazquez EJ, Lee KL. Genetic variants are not associated with outcome in patients with coronary artery disease and left ventricular dysfunction: results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trials. Cardiology. 2015; 130(2):69-81.
    View in: PubMed
    Score: 0.007
  53. Leary PJ, Barr RG, Bluemke DA, Bristow MR, Kronmal RA, Lima JA, Ralph DD, Ventetuolo CE, Kawut SM. H2 receptor antagonists and right ventricular morphology: the MESA right ventricle study. Ann Am Thorac Soc. 2014 Nov; 11(9):1379-86.
    View in: PubMed
    Score: 0.007
  54. Abraham WT, Lowes BD, White M, Ferguson DA, Scheffel CA, Wolfel EE, Lindenfeld J, Bristow MR. Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure. J Card Fail. 1994 Oct; 1(1):57-62.
    View in: PubMed
    Score: 0.007
  55. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994 Jul-Aug; 13(4):S107-12.
    View in: PubMed
    Score: 0.007
  56. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation. 1994 Apr; 89(4):1632-42.
    View in: PubMed
    Score: 0.007
  57. Bristow MR. Use of oral enoximone in pharmacologic bridging to cardiac transplantation. Z Kardiol. 1994; 83 Suppl 2:15-9.
    View in: PubMed
    Score: 0.007
  58. Olsen SL, Renlund DG, O'Connell JB, Taylor DO, Lassetter JE, Eastburn TE, Hammond EH, Bristow MR. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation. 1993 Aug; 56(2):359-62.
    View in: PubMed
    Score: 0.007
  59. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, Bristow MR. Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart. Circulation. 1993 Aug; 88(2):472-80.
    View in: PubMed
    Score: 0.007
  60. Kao DP, Wagner BD, Robertson AD, Bristow MR, Lowes BD. A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol. PLoS One. 2012; 7(11):e48184.
    View in: PubMed
    Score: 0.006
  61. Leary PJ, Barr RG, Bluemke DA, Bristow MR, Hough CL, Kronmal RA, Lima JA, McClelland RL, Tracy RP, Kawut SM. Von Willebrand factor and the right ventricle (the MESA-Right Ventricle Study). Am J Cardiol. 2012 Dec 15; 110(12):1846-51.
    View in: PubMed
    Score: 0.006
  62. Kawut SM, Barr RG, Lima JA, Praestgaard A, Johnson WC, Chahal H, Ogunyankin KO, Bristow MR, Kizer JR, Tandri H, Bluemke DA. Right ventricular structure is associated with the risk of heart failure and cardiovascular death: the Multi-Ethnic Study of Atherosclerosis (MESA)--right ventricle study. Circulation. 2012 Oct 02; 126(14):1681-8.
    View in: PubMed
    Score: 0.006
  63. Anderson FL, Port JD, Reid BB, Hanson G, Kralios AC, Hershberger RE, Bristow MR. Effect of therapeutic dopamine administration on myocardial catecholamine and neuropeptide Y concentrations in the failing ventricles of patients with idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol. 1992; 20(5):800-6.
    View in: PubMed
    Score: 0.006
  64. Bristow MR, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, O'Connell JB, Renlund DG, Volkman K, Murray J, et al. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991 Sep; 84(3):1024-39.
    View in: PubMed
    Score: 0.006
  65. O'Connell JB, Renlund DG, Hammond EH, Wittwer CT, Yowell RL, DeWitt CW, Jones KW, Gay WA, Menlove RL, Bristow MR. Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss. J Heart Lung Transplant. 1991 Mar-Apr; 10(2):217-21; discussion 221-2.
    View in: PubMed
    Score: 0.006
  66. Dibble CT, Lima JAC, Bluemke DA, Chirinos JA, Chahal H, Bristow MR, Kronmal RA, Barr RG, Ferrari VA, Propert KJ, Kawut SM. Regional left ventricular systolic function and the right ventricle: the multi-ethnic study of atherosclerosis right ventricle study. Chest. 2011 Aug; 140(2):310-316.
    View in: PubMed
    Score: 0.006
  67. Ventetuolo CE, Ouyang P, Bluemke DA, Tandri H, Barr RG, Bagiella E, Cappola AR, Bristow MR, Johnson C, Kronmal RA, Kizer JR, Lima JA, Kawut SM. Sex hormones are associated with right ventricular structure and function: The MESA-right ventricle study. Am J Respir Crit Care Med. 2011 Mar 01; 183(5):659-67.
    View in: PubMed
    Score: 0.006
  68. Carson P, Fiuzat M, O'Connor C, Anand I, Plehn J, Lindenfeld JA, Silver M, White M, Miller A, Davis G, Robertson AD, Bristow M, Gottlieb S. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (?-Blocker Evaluation of Survival Trial [BEST]). Am Heart J. 2010 Oct; 160(4):649-54.
    View in: PubMed
    Score: 0.006
  69. Drakos SG, Kfoury AG, Hammond EH, Reid BB, Revelo MP, Rasmusson BY, Whitehead KJ, Salama ME, Selzman CH, Stehlik J, Clayson SE, Bristow MR, Renlund DG, Li DY. Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart. J Am Coll Cardiol. 2010 Jul 27; 56(5):382-91.
    View in: PubMed
    Score: 0.005
  70. Port JD, Gilbert EM, Larrabee P, Mealey P, Volkman K, Ginsburg R, Hershberger RE, Murray J, Bristow MR. Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart. Circulation. 1990 Mar; 81(3):929-38.
    View in: PubMed
    Score: 0.005
  71. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990 Mar; 88(3):223-9.
    View in: PubMed
    Score: 0.005
  72. Metra M, Eichhorn E, Abraham WT, Linseman J, B?hm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. 2009 Dec; 30(24):3015-26.
    View in: PubMed
    Score: 0.005
  73. Hegewald MG, O'Connell JB, Renlund DG, Lee HR, Burton NA, Karwande SV, Jones KW, Lassetter JE, Bristow MR. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation. J Heart Transplant. 1989 Jul-Aug; 8(4):303-9; discussion 309-10.
    View in: PubMed
    Score: 0.005
  74. O'Connell JB, Renlund DG, Gay WA, DeWitt CW, Hammond EH, Yowell RL, Jones KW, Karwande SV, Doty DB, Bristow MR. Efficacy of OKT3 retreatment for refractory cardiac allograft rejection. Transplantation. 1989 May; 47(5):788-92.
    View in: PubMed
    Score: 0.005
  75. Bristow MR, Hershberger RE, Port JD, Minobe W, Rasmussen R. Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol. 1989 Mar; 35(3):295-303.
    View in: PubMed
    Score: 0.005
  76. Taylor MR, Slavov D, Humphrey K, Zhao L, Cockroft J, Zhu X, Lavori P, Bristow MR, Mestroni L, Lazzeroni LC. Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics. 2009 Jan; 19(1):35-43.
    View in: PubMed
    Score: 0.005
  77. MacGregor JF, Wachter SB, Munger M, Stoddard G, Bristow MR, Gilbert EM. Carvedilol produces sustained long-term benefits: follow-up at 12 years. Congest Heart Fail. 2009 Jan-Feb; 15(1):5-8.
    View in: PubMed
    Score: 0.005
  78. Watson FS, O'Connell JB, Amber IJ, Renlund DG, Classen D, Johnston JM, Smith CB, Bristow MR. Treatment of cytomegalovirus pneumonia in heart transplant recipients with 9(1,3-dihydroxy-2-proproxymethyl)-guanine (DHPG). J Heart Transplant. 1988 Mar-Apr; 7(2):102-5.
    View in: PubMed
    Score: 0.005
  79. Gilbert EM, Renlund DG, O'Connell JB, Eiswirth CC, Rothstein G, Gay WA, Bristow MR. Immunosuppressive efficacy of vincristine in heart transplantation: a preliminary report. J Heart Transplant. 1987 Nov-Dec; 6(6):369-74.
    View in: PubMed
    Score: 0.005
  80. Tate CW, Robertson AD, Zolty R, Shakar SF, Lindenfeld J, Wolfel EE, Bristow MR, Lowes BD. Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST). J Card Fail. 2007 Nov; 13(9):732-7.
    View in: PubMed
    Score: 0.005
  81. Lowes BD, Zolty R, Shakar SF, Brieke A, Gray N, Reed M, Calalb M, Minobe W, Lindenfeld J, Wolfel EE, Geraci M, Bristow MR, Cleveland J. Assist devices fail to reverse patterns of fetal gene expression despite beta-blockers. J Heart Lung Transplant. 2007 Nov; 26(11):1170-6.
    View in: PubMed
    Score: 0.005
  82. Feldman AM, Oren RM, Abraham WT, Boehmer JP, Carson PE, Eichhorn E, Gilbert EM, Kao A, Leier CV, Lowes BD, Mathier MA, McGrew FA, Metra M, Zisman LS, Shakar SF, Krueger SK, Robertson AD, White BG, Gerber MJ, Wold GE, Bristow MR. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial. Am Heart J. 2007 Nov; 154(5):861-9.
    View in: PubMed
    Score: 0.004
  83. Renlund DG, Gilbert EM, O'Connell JB, Gay WA, Jones KW, Burton NA, Doty DB, Karwande SV, Dewitt CW, Menlove RL, Herrick CM, Bristow MR. Age-associated decline in cardiac allograft rejection. Am J Med. 1987 09; 83(3):391-8.
    View in: PubMed
    Score: 0.004
  84. Sparagna GC, Chicco AJ, Murphy RC, Bristow MR, Johnson CA, Rees ML, Maxey ML, McCune SA, Moore RL. Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure. J Lipid Res. 2007 Jul; 48(7):1559-70.
    View in: PubMed
    Score: 0.004
  85. Gilbert EM, Eiswirth CC, Renlund DG, Menlove RL, DeWitt CW, Freedman LA, Herrick CM, Gay WA, Bristow MR. Use of Orthoclone OKT3 monoclonal antibody in cardiac transplantation: early experience with rejection prophylaxis and treatment of refractory rejection. Transplant Proc. 1987 Apr; 19(2 Suppl 1):45-53.
    View in: PubMed
    Score: 0.004
  86. Taylor MR, Slavov D, Ku L, Di Lenarda A, Sinagra G, Carniel E, Haubold K, Boucek MM, Ferguson D, Graw SL, Zhu X, Cavanaugh J, Sucharov CC, Long CS, Bristow MR, Lavori P, Mestroni L. Prevalence of desmin mutations in dilated cardiomyopathy. Circulation. 2007 Mar 13; 115(10):1244-51.
    View in: PubMed
    Score: 0.004
  87. Gilbert EM, Dewitt CW, Eiswirth CC, Renlund DG, Menlove RL, Freedman LA, Herrick CM, Gay WA, Bristow MR. Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am J Med. 1987 Feb; 82(2):202-6.
    View in: PubMed
    Score: 0.004
  88. Taylor MRG, Ku L, Slavov D, Cavanaugh J, Boucek M, Zhu X, Graw S, Carniel E, Barnes C, Quan D, Prall R, Lovell MA, Mierau G, Ruegg P, Mandava N, Bristow MR, Towbin JA, Mestroni L. Danon disease presenting with dilated cardiomyopathy and a complex phenotype. J Hum Genet. 2007; 52(10):830-835.
    View in: PubMed
    Score: 0.004
  89. Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, Feldman AM, Galle E, Ecklund F. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation. 2006 Dec 19; 114(25):2766-72.
    View in: PubMed
    Score: 0.004
  90. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation. 1986 Dec; 74(6):1290-302.
    View in: PubMed
    Score: 0.004
  91. Freter CE, Lee TC, Billingham ME, Chak L, Bristow MR. Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review. Am J Med. 1986 Mar; 80(3):483-5.
    View in: PubMed
    Score: 0.004
  92. Bullinga JR, Alharethi R, Schram MS, Bristow MR, Gilbert EM. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. J Card Fail. 2005 Dec; 11(9):693-9.
    View in: PubMed
    Score: 0.004
  93. Sam F, Kerstetter DL, Pimental DR, Mulukutla S, Tabaee A, Bristow MR, Colucci WS, Sawyer DB. Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Card Fail. 2005 Aug; 11(6):473-80.
    View in: PubMed
    Score: 0.004
  94. Domanski M, Fleg J, Bristow M, Knox S. The effect of gender on outcome in digitalis-treated heart failure patients. J Card Fail. 2005 Mar; 11(2):83-6.
    View in: PubMed
    Score: 0.004
  95. Shakar SF, Lowes BD, Lindenfeld J, Zolty R, Simon M, Robertson AD, Bristow MR, Wolfel EE. Peak oxygen consumption and outcome in heart failure patients chronically treated with beta-blockers. J Card Fail. 2004 Feb; 10(1):15-20.
    View in: PubMed
    Score: 0.003
  96. Zisman LS, Meixell GE, Bristow MR, Canver CC. Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation. 2003 Oct 07; 108(14):1679-81.
    View in: PubMed
    Score: 0.003
  97. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003 Sep 03; 42(5):914-22.
    View in: PubMed
    Score: 0.003
  98. Abraham WT, Raynolds MV, Badesch DB, Wynne KM, Groves BM, Roden RL, Robertson AD, Lowes BD, Zisman LS, Voelkel NF, Bristow MR, Perryman MB. Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics. J Renin Angiotensin Aldosterone Syst. 2003 Mar; 4(1):27-30.
    View in: PubMed
    Score: 0.003
  99. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003 Feb 19; 289(7):871-8.
    View in: PubMed
    Score: 0.003
  100. Bohlmeyer T, Ferdensi A, Bristow MR, Takahashi S, Zisman LS. Selective activation of N-acyl-D-glucosamine 2-epimerase expression in failing human heart ventricular myocytes. J Card Fail. 2003 Feb; 9(1):59-68.
    View in: PubMed
    Score: 0.003
  101. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982 Jul 22; 307(4):205-11.
    View in: PubMed
    Score: 0.003
  102. Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer. 1982 Jul 01; 50(1):32-41.
    View in: PubMed
    Score: 0.003
  103. Communal C, Colucci WS, Remondino A, Sawyer DB, Port JD, Wichman SE, Bristow MR, Singh K. Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium. J Card Fail. 2002 Apr; 8(2):86-92.
    View in: PubMed
    Score: 0.003
  104. Bristow MR, Ginsburg R, Kantrowitz NE, Baim DS, Rosenbaum JT. Coronary spasm associated with urticaria: report of a case mimicking anaphylaxis. Clin Cardiol. 1982 Mar; 5(3):238-40.
    View in: PubMed
    Score: 0.003
  105. Lindenfeld J, Robertson AD, Lowes BD, Bristow MR. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. J Am Coll Cardiol. 2001 Dec; 38(7):1950-6.
    View in: PubMed
    Score: 0.003
  106. Loh E, Elkayam U, Cody R, Bristow M, Jaski B, Colucci WS. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. J Card Fail. 2001 Jun; 7(2):114-21.
    View in: PubMed
    Score: 0.003
  107. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, Packer M. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001 May 03; 344(18):1358-65.
    View in: PubMed
    Score: 0.003
  108. Schleman KA, Lindenfeld JA, Lowes BD, Bristow MR, Ferguson D, Wolfel EE, Abraham WT, Zisman LS. Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. J Card Fail. 2001 Mar; 7(1):4-12.
    View in: PubMed
    Score: 0.003
  109. Noori A, Lindenfeld J, Wolfel E, Ferguson D, Bristow MR, Lowes BD. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. 2000 Jun; 6(2):115-9.
    View in: PubMed
    Score: 0.003
  110. Miyata S, Minobe W, Bristow MR, Leinwand LA. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res. 2000 Mar 03; 86(4):386-90.
    View in: PubMed
    Score: 0.003
  111. Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, Gilbert EM. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol. 1999 Apr 15; 83(8):1201-5.
    View in: PubMed
    Score: 0.003
  112. Bowling N, Walsh RA, Song G, Estridge T, Sandusky GE, Fouts RL, Mintze K, Pickard T, Roden R, Bristow MR, Sabbah HN, Mizrahi JL, Gromo G, King GL, Vlahos CJ. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation. 1999 Jan 26; 99(3):384-91.
    View in: PubMed
    Score: 0.002
  113. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am J Med. 1978 Nov; 65(5):823-32.
    View in: PubMed
    Score: 0.002
  114. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep. 1978 Jun; 62(6):873-9.
    View in: PubMed
    Score: 0.002
  115. Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, Robertson AD, Bristow MR, Schrier RW. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998 Mar; 4(1):37-44.
    View in: PubMed
    Score: 0.002
  116. Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978 Feb; 88(2):168-75.
    View in: PubMed
    Score: 0.002
  117. Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA. Myosin heavy chain gene expression in human heart failure. J Clin Invest. 1997 Nov 01; 100(9):2362-70.
    View in: PubMed
    Score: 0.002
  118. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail. 1997 Sep; 3(3):173-9.
    View in: PubMed
    Score: 0.002
  119. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996 Dec 01; 94(11):2800-6.
    View in: PubMed
    Score: 0.002
  120. Taylor DO, Bristow MR, O'Connell JB, Price GD, Hammond EH, Doty DB, Karwande SV, Gay WA, Jones KW, Lapp? D, Renlund DG. Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy. J Heart Lung Transplant. 1996 Oct; 15(10):1039-46.
    View in: PubMed
    Score: 0.002
  121. Wagoner LE, Taylor DO, Olsen SL, Bristow MR, O'Connell JB, Hammond EH, Lappe DL, Renlund DG. Cyclophosphamide in cardiac transplant recipients with frequent rejection: a six-year retrospective review. Clin Transplant. 1996 Oct; 10(5):437-43.
    View in: PubMed
    Score: 0.002
  122. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23; 334(21):1349-55.
    View in: PubMed
    Score: 0.002
  123. Renlund DG, Taylor DO, Ensley RD, O'Connell JB, Gilbert EM, Bristow MR, Ma H, Yanowitz FG. Exercise capacity after heart transplantation: influence of donor and recipient characteristics. J Heart Lung Transplant. 1996 Jan; 15(1 Pt 1):16-24.
    View in: PubMed
    Score: 0.002
  124. Costanzo MR, Augustine S, Bourge R, Bristow M, O'Connell JB, Driscoll D, Rose E. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation. 1995 Dec 15; 92(12):3593-612.
    View in: PubMed
    Score: 0.002
  125. Taylor DO, Bristow MR, O'Connell JB, Ensley RD, Olsen SL, Hammond EH, Wagoner LE, Renlund DG. A prospective, randomized comparison of cyclophosphamide and azathioprine for early rejection prophylaxis after cardiac transplantation. Decreased sensitization to OKT3. Transplantation. 1994 Sep 27; 58(6):645-9.
    View in: PubMed
    Score: 0.002
  126. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993 Dec 11; 342(8885):1441-6.
    View in: PubMed
    Score: 0.002
  127. Wagoner LE, Olsen SL, Bristow MR, O'Connell JB, Taylor DO, Lappe DL, Renlund DG. Cyclophosphamide as an alternative to azathioprine in cardiac transplant recipients with suspected azathioprine-induced hepatotoxicity. Transplantation. 1993 Dec; 56(6):1415-8.
    View in: PubMed
    Score: 0.002
  128. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman LS, Taft CS, Perryman MB. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet. 1993 Oct 30; 342(8879):1073-5.
    View in: PubMed
    Score: 0.002
  129. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med. 1993 Jul 15; 329(3):149-55.
    View in: PubMed
    Score: 0.002
  130. Olsen SL, Wagoner LE, Hammond EH, Taylor DO, Yowell RL, Ensley RD, Bristow MR, O'Connell JB, Renlund DG. Vascular rejection in heart transplantation: clinical correlation, treatment options, and future considerations. J Heart Lung Transplant. 1993 Mar-Apr; 12(2):S135-42.
    View in: PubMed
    Score: 0.002
  131. Hammond EH, Yowell RL, Price GD, Menlove RL, Olsen SL, O'Connell JB, Bristow MR, Doty DB, Millar RC, Karwande SV, et al. Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant. 1992 May-Jun; 11(3 Pt 2):S111-9.
    View in: PubMed
    Score: 0.002
  132. Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB, Resta S, Dunn D, Gamberg P, Ratkovec RM, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med. 1992 Apr 30; 326(18):1182-6.
    View in: PubMed
    Score: 0.002
  133. Price GD, Olsen SL, Taylor DO, O'Connell JB, Bristow MR, Renlund DG. Corticosteroid-free maintenance immunosuppression after heart transplantation: feasibility and beneficial effects. J Heart Lung Transplant. 1992 Mar-Apr; 11(2 Pt 2):403-14.
    View in: PubMed
    Score: 0.002
  134. Marks JD, Karwande SV, Richenbacher WE, Jones KW, Doty DB, Millar RC, O'Connell JB, Renlund DG, Bristow MR, Pantalos GM, et al. Perioperative mechanical circulatory support for transplantation. J Heart Lung Transplant. 1992 Jan-Feb; 11(1 Pt 1):117-28.
    View in: PubMed
    Score: 0.002
  135. Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC. Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest. 1991 Jul; 88(1):15-9.
    View in: PubMed
    Score: 0.001
  136. Moore CK, O'Connell JB, Renlund DG, Bristow MR, Hammond EH. Cardiac allograft cellular rejection during OKT3 prophylaxis in the absence of sensitization. Transplant Proc. 1991 Feb; 23(1 Pt 2):1055-8.
    View in: PubMed
    Score: 0.001
  137. Ensley RD, Hammond EH, Renlund DG, Yowell RL, Bristow MR, DeWitt CW, Menlove RL, Ratkovec RM, O'Connell JB. Clinical manifestations of vascular rejection in cardiac transplantation. Transplant Proc. 1991 Feb; 23(1 Pt 2):1130-2.
    View in: PubMed
    Score: 0.001
  138. O'Connell JB, Renlund DG, Bristow MR, Hammond EH. Detection of allograft endothelial cells of recipient origin following ABO-compatible, nonidentical cardiac transplantation. Transplantation. 1991 Feb; 51(2):438-42.
    View in: PubMed
    Score: 0.001
  139. O'Connell JB, Bristow MR, Rasmussen LG, Ratkovec RM, Gay WA, Jones KW, Renlund DG. Cardiac allograft function with corticosteroid-free maintenance immunosuppression. Circulation. 1990 Nov; 82(5 Suppl):IV318-21.
    View in: PubMed
    Score: 0.001
  140. Ratkovec RM, Wray RB, Renlund DG, O'Connell JB, Bristow MR, Gay WA, Karwande SV, Doty DB, Millar RC, Menlove RL, et al. Influence of corticosteroid-free maintenance immunosuppression on allograft coronary artery disease after cardiac transplantation. J Thorac Cardiovasc Surg. 1990 Jul; 100(1):6-12.
    View in: PubMed
    Score: 0.001
  141. Moore CK, Bristow MR, Renlund DG, Rasmussen LG, O'Connell JB. Long-term morbidity of cyclosporine with corticosteroid-free maintenance immunosuppression in cardiac transplantation. Transplant Proc. 1990 Jun; 22(3 Suppl 1):25-9.
    View in: PubMed
    Score: 0.001
  142. Hammond EH, Watson FS, Bristow MR, O'Connell JB, Gilbert EM, Doty DB, Renlund DG. Fibrinoid necrosis of a temporal artery complicating the treatment of refractory cardiac allograft rejection with murine monoclonal CD3 antibody (OKT3). J Heart Transplant. 1990 May-Jun; 9(3 Pt 1):236-8.
    View in: PubMed
    Score: 0.001
  143. Hammond EH, Yowell RL, Nunoda S, Menlove RL, Renlund DG, Bristow MR, Gay WA, Jones KW, O'Connell JB. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant. 1989 Nov-Dec; 8(6):430-43.
    View in: PubMed
    Score: 0.001
  144. Movsesian MA, Bristow MR, Krall J. Ca2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. Circ Res. 1989 Oct; 65(4):1141-4.
    View in: PubMed
    Score: 0.001
  145. Renlund DG, Bristow MR, Crandall BG, Burton NA, Doty DB, Karwande SV, Gay WA, Jones KW, Hegewald MG, Hagan ME, et al. Hypercholesterolemia after heart transplantation: amelioration by corticosteroid-free maintenance immunosuppression. J Heart Transplant. 1989 May-Jun; 8(3):214-9; discussion 219-20.
    View in: PubMed
    Score: 0.001
  146. Feldman AM, Cates AE, Bristow MR, Van Dop C. Altered expression of alpha-subunits of G proteins in failing human hearts. J Mol Cell Cardiol. 1989 Apr; 21(4):359-65.
    View in: PubMed
    Score: 0.001
  147. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989 Mar; 79(3):483-90.
    View in: PubMed
    Score: 0.001
  148. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, Van Dop C. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest. 1988 Jul; 82(1):189-97.
    View in: PubMed
    Score: 0.001
  149. Gilbert EM, Bristow MR, Mason JW. Acute hemodynamic response to low dose enoximone (MDL 17,043): an oral dose-range study. Am J Cardiol. 1987 Aug 14; 60(5):57C-62C.
    View in: PubMed
    Score: 0.001
  150. Renlund DG, Bristow MR, Burton NA, Jones KW, Karwande SV, Gay WA. Survival following cardiac transplantation--what are acceptable standards? West J Med. 1987 May; 146(5):627-30.
    View in: PubMed
    Score: 0.001
  151. Schroeder JS, Beier-Scott L, Ginsburg R, Bristow MR, McAuley BJ. Efficacy of diltiazem for medically refractory stable angina: long-term follow-up. Clin Cardiol. 1985 Sep; 8(9):480-5.
    View in: PubMed
    Score: 0.001
  152. Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, Kohler M, Brown BW, Billingham ME. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983 Dec; 99(6):745-9.
    View in: PubMed
    Score: 0.001
  153. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J. 1983 Nov; 106(5 Pt 1):1048-56.
    View in: PubMed
    Score: 0.001
  154. Ginsburg R, Bristow MR, Billingham ME, Stinson EB, Schroeder JS, Harrison DC. Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. Am Heart J. 1983 Sep; 106(3):535-40.
    View in: PubMed
    Score: 0.001
  155. Schroeder JS, Lamb IH, Bristow MR, Ginsburg R, Hung J, McAuley BJ. Prevention of cardiovascular events in variant angina by long-term diltiazem therapy. J Am Coll Cardiol. 1983 Jun; 1(6):1507-11.
    View in: PubMed
    Score: 0.001
  156. Schroeder JS, Lamb IH, Ginsburg R, Bristow MR, Hung J. Diltiazem for long-term therapy of coronary arterial spasm. Am J Cardiol. 1982 Feb 18; 49(3):533-7.
    View in: PubMed
    Score: 0.001
  157. Ginsburg R, Bristow MR, Kantrowitz N, Baim DS, Harrison DC. Histamine provocation of clinical coronary artery spasm: implications concerning pathogenesis of variant angina pectoris. Am Heart J. 1981 Nov; 102(5):819-22.
    View in: PubMed
    Score: 0.001
  158. Ginsburg R, Stinson EB, Bristow MR, Schroeder JS. Coronary-artery spasm after revascularization. N Engl J Med. 1981 Sep 17; 305(12):699.
    View in: PubMed
    Score: 0.001
  159. Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep. 1978 Jun; 62(6):857-64.
    View in: PubMed
    Score: 0.001
  160. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978 Jun; 62(6):865-72.
    View in: PubMed
    Score: 0.001
  161. Billingham ME, Bristow MR, Glatstein E, Mason JW, Masek MA, Daniels JR. Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol. 1977 Mar; 1(1):17-23.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)